secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeyondSpring Inc. (BYSI)
CIK:        0001677940
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001171843-25-007217
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeyondSpring Q3 2025 net loss $1.7M; Plinabulin DCR 85% in NSCLC post-PD-1/L1
-----------------------------------------------------------------------------

- Net loss from continuing ops $1.7M vs $2.2M YoY; cash $12.5M up from $2.9M Dec 2024.
- Plinabulin + docetaxel + Keytruda in NSCLC: DCR 85%, median PFS 7.0 mo, 12-mo OS 79%.
- SEED (38% owned) closed $30M Series A-3, FDA/NMPA IND clearance for RBM39 degrader.
- R&D $1.0M, G&A $0.8M; headcount reductions drove lower admin expenses.
- Discontinued ops (SEED sale accounting) net loss $3.2M in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325007217/0001171843-25-007217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325007217/f8k_111225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer